| Project/Area Number |
23701088
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 非ホジキンリンパ腫 / 血清miRNA / miR-92a / 診断マーカー |
|---|
| Research Abstract |
To evaluate the clinical relevance of the miR-92a in plasma obtained from non-Hodgkin's lymphoma patients, because miR-92 miRNA plays a crucial role in lymphogenesis, as well as tumorigenesis in lymphoid tissue. We evaluated plasma miR-92a value; MicroRNA Assays with modifications with non-Hodgkin's lymphoma and compared results with healthy subjects. Plasma miR-92a values in non-Hodgkin's lymphoma were extremely low, compared to healthy subjects. At the time of diagnosis The down-regulated plasma miR-92a increased in the complete response phase, reaching normal control levels, and again becoming down-regulated in the relapse phase. In non-Hodgkin's lymphoma patients, while a decreased level of plasma miR-92a was evident, indicating that the discrepancy lymph circulating miR-92a might be an important clinical issue. The plasma miR-92a value could be a novel biomarker for monitoring lymphoma patients, especially in those with indolent lymphoma.
|
